Toll-like receptors and bacterial endophthalmitis
Toll样受体与细菌性眼内炎
基本信息
- 批准号:8387011
- 负责人:
- 金额:$ 27.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-01-01 至 2014-12-31
- 项目状态:已结题
- 来源:
- 关键词:AgingAgonistAntibiotic ResistanceAstrocytesBacteriaBacterial InfectionsBiological PreservationBlindnessCataract ExtractionCellsCellular InfiltrationComplicationDataDefense MechanismsDevelopmentDiseaseDisease OutcomeDown-RegulationEndophthalmitisEnvironmentEyeFutureGoalsHydrochloride SaltImmuneImmune responseImmune systemIn VitroIncidenceInfectionInfection preventionInflammationInflammatoryInflammatory ResponseInjuryInvadedKnock-outKnowledgeLeadLearningLigandsLightMediatingMediator of activation proteinMicrogliaMusNatural ImmunityNeedlesOlder PopulationOperative Surgical ProceduresOutcomePathogenesisPathway interactionsPatientsPattern recognition receptorPenetrating Eye InjuriesPlayPopulationPreventionProceduresProductionPropertyReceptor SignalingRegulationRetinaRetinalRoleSeveritiesSignal PathwaySignal TransductionStaphylococcus aureusSterilityTLR2 geneTestingToll-like receptorsUnited StatesUp-RegulationVirulence FactorsVisionVisualagedantimicrobial peptidebacterial endophthalmitisbasecathelicidincathelicidin antimicrobial peptidechemokineclinically relevantcytokinein vivoinsightintravitreal injectionkillingsmicrobialmouse modelnew therapeutic targetnovel therapeuticspathogenpreventprotective effectrapid detectionresponseretinal damage
项目摘要
ABSTRACT
Bacterial endophthalmitis is a vision-threatening complication of penetrating eye injury and intraocular
surgery, notably cataract surgery, the most common ophthalmic procedure performed in older populations in
the United States. Approximately, 3 out of 1000 patients develop bacterial endophthalmitis after cataract
surgery. As the aged population in the US is expected to grow dramatically, the number of cataract surgeries
performed will also increase significantly, resulting in a proportional increase in the incidence of
endophthalmitis. The visual properties of the retina are highly sensitive to inflammation-caused damage
therefore, a rapid detection and clearance of invading pathogens is critical in minimizing retinal damage. The
recent discovery presented in the preliminary data revealed that the retina responds to the TLR2 agonist
Pam3Cys by producing the mediators of innate immunity, and that intravitreal injection of Pam3Cys, prior to
bacterial infection, completely prevented the development of Staphylococcus aureus (SA) endophthalmitis in
C57BL/6 (B6) mice. This leads to the hypothesis that TLR2 plays a critical role in retinal innate immune
response to S. aureus and that activation and signaling through TLR determines the disease outcome. The
objective of this proposal is to elucidate the mechanisms by which TLR2 activation prevents the development
of SA endophthalmitis. Three specific aims are proposed: 1) To determine the role of TLR2 in retinal innate
response against SA, and how TLR2 signaling is modulated by Pam3Cys pretreatment. The innate response
will be tested in normal, TLR2 ligand, and the SA challenged B6 mouse retinas and cultured retinal (microglia,
astrocytes, Muller and RPE) cells by assessing TLR-mediated cell signaling and production of proinflammatory
cytokines/chemokines, 2) To determine the mechanisms of TLR2 ligand-induced stimulation of protective
retinal innate immunity. Activation of TLR2 prior to infection induces protective mechanisms mainly by down-
regulating proinflammatory (Th1) cytokines and up-regulating antimicrobial peptides (AMPs) in the retina
upon subsequent bacterial challenge. TLR2-/- and MyD88-/- mice will be used to determine whether these
mechanisms are TLR2/MyD88 dependent, active against other bacteria, and are effective in a mouse model of
intravitreal injection-associated SA endophthalmitis. 3) To determine the role of cathelicidin related
antimicrobial peptide (CRAMP) in retinal innate responses during SA endophthalmitis. The TLR signaling
pathways involved in CRAMP induction and mechanisms by which CRAMP modulates bacterial clearance and
preservation of retinal integrity, will be tested using cultured retinal cells and CRAMP knockout (Cnlp-/-) mice.
Completion of these aims should provide insight into the understanding of the retinal innate response to
microbial pathogens, and may lead to the identification of new therapeutic targets for preventing surgery-
associated endophthalmitis.
摘要
细菌性眼内炎是眼球穿通伤和眼内感染的一种威胁视力的并发症,
手术,特别是白内障手术,是老年人中最常见的眼科手术,
美国的大约每1000名患者中就有3名在白内障后出现细菌性眼内炎
手术随着美国老年人口的急剧增长,白内障手术的数量
也将大大增加,导致发病率成比例增加,
眼内炎视网膜的视觉特性对炎症引起的损伤高度敏感
因此,快速检测和清除入侵的病原体对于最小化视网膜损伤至关重要。的
在初步数据中提出的最近发现揭示了视网膜对TLR2激动剂的反应
Pam3Cys通过产生先天免疫介质,以及在免疫前玻璃体内注射Pam3Cys,
细菌感染,完全防止了金黄色葡萄球菌(SA)眼内炎的发展,
C57BL/6(B6)小鼠。这导致了TLR2在视网膜先天免疫中起关键作用的假设。
响应S。金黄色葡萄球菌和激活和信号通过TLR决定疾病的结果。的
本提案的目的是阐明TLR2激活阻止发展的机制,
SA眼内炎。本研究的目的有三:1)确定TLR2在视网膜先天性损害中的作用,
对SA的应答,以及Pam3Cys预处理如何调节TLR2信号传导。先天免疫反应
将在正常、TLR2配体和SA攻击的B6小鼠视网膜和培养的视网膜(小胶质细胞,
星形胶质细胞、Muller和RPE)细胞通过评估TLR介导的细胞信号传导和促炎性细胞因子的产生来检测。
2)为了确定TLR2配体诱导的保护性刺激的机制,
视网膜先天免疫感染前TLR2的激活主要通过下调-
调节视网膜中的促炎(Th1)细胞因子和上调抗微生物肽(AMP)
在随后的细菌挑战中。将使用TLR2-/-和MyD88-/-小鼠来确定这些小鼠是否是正常的。
这种机制是TLR2/MyD88依赖性的,对其他细菌有活性,并且在小鼠模型中有效。
玻璃体内注射相关SA眼内炎。3)确定cathelicidin相关的作用
抗微生物肽(CRAMP)在SA眼内炎期间视网膜先天反应中的作用。tlr信号
参与CRAMP诱导的途径和CRAMP调节细菌清除的机制,
将使用培养的视网膜细胞和CRAMP敲除(Cnlp-/-)小鼠测试视网膜完整性的保存。
这些目标的完成应该提供深入了解视网膜的先天反应,
微生物病原体,并可能导致识别新的治疗靶点,以防止手术-
相关性眼内炎。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ashok Kumar其他文献
Ashok Kumar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ashok Kumar', 18)}}的其他基金
ADAR1-mediated antiviral response in Zika virus (ZIKV) infection
ADAR1 介导的寨卡病毒 (ZIKV) 感染抗病毒反应
- 批准号:
10621913 - 财政年份:2022
- 资助金额:
$ 27.72万 - 项目类别:
ADAR1-mediated antiviral response in Zika virus (ZIKV) infection
ADAR1 介导的寨卡病毒 (ZIKV) 感染抗病毒反应
- 批准号:
10373627 - 财政年份:2022
- 资助金额:
$ 27.72万 - 项目类别:
Age-associated impaired executive function: Rescue by NMDA receptor upregulation
与年龄相关的执行功能受损:通过 NMDA 受体上调来挽救
- 批准号:
10033493 - 财政年份:2020
- 资助金额:
$ 27.72万 - 项目类别:
Role of ABCG1 in Zika virus induced chorioretinal atrophy
ABCG1 在寨卡病毒诱导的脉络膜视网膜萎缩中的作用
- 批准号:
9436896 - 财政年份:2018
- 资助金额:
$ 27.72万 - 项目类别:
Role of AMP-activated protein kinase in bacterial endophthalmitis - Diversity Supplement
AMP 激活蛋白激酶在细菌性眼内炎中的作用 - Diversity Supplement
- 批准号:
10206590 - 财政年份:2017
- 资助金额:
$ 27.72万 - 项目类别:
Role of AMP-activated protein kinase in bacterial endophthalmitis
AMP 激活蛋白激酶在细菌性眼内炎中的作用
- 批准号:
9899998 - 财政年份:2017
- 资助金额:
$ 27.72万 - 项目类别:
Targeting NAD metabolism to ameliorate bacterial endophthalmitis
靶向 NAD 代谢改善细菌性眼内炎
- 批准号:
10445516 - 财政年份:2017
- 资助金额:
$ 27.72万 - 项目类别:
Mechanisms of Inflammation Resolution in Bacterial Endophthalmitis
细菌性眼内炎的炎症消退机制
- 批准号:
10231125 - 财政年份:2017
- 资助金额:
$ 27.72万 - 项目类别:
Targeting NAD metabolism to ameliorate bacterial endophthalmitis
靶向 NAD 代谢改善细菌性眼内炎
- 批准号:
10621770 - 财政年份:2017
- 资助金额:
$ 27.72万 - 项目类别:
Mechanisms of Inflammation Resolution in Bacterial Endophthalmitis
细菌性眼内炎的炎症消退机制
- 批准号:
10002232 - 财政年份:2017
- 资助金额:
$ 27.72万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 27.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 27.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)